

Global X Genomics & Biotechnology UCITS ETF (GNOM)

USD Accumulating Share Class
As of 28 Feb 2026



KEY FEATURES

All information below correct as of 28 February 2026



High Growth Potential

Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.



Structural Tailwinds

The cost of genomic sequencing has dropped from nearly \$100mm per genome in 2002 to less than \$1,000 in 2020. Adoption has continued to rise, as costs plummet (Source: National Human Genome Research Institute, Nov 2021).



Targeted Exposure

The ETF provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

Capital at Risk. All financial investments involve an element of risk. Therefore, the value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed.

FUND DETAILS

Inception Date	02 November 2021
Underlying Index	Solactive Genomics v2 Index
Number of Holdings	48
Assets Under Management	\$21,676,811
Total Expense Ratio	0.50%
Ongoing Charges ¹	0.50%
Management Style	Physical - Full Replication
Domicile	Ireland
Registered Countries	Austria, Denmark, Finland, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Singapore [Restricted], Spain, Sweden, Switzerland, United Kingdom

TRADING DETAILS

Primary Ticker	GNOM
Primary ISIN	IE00BM8RON95
Index Ticker	SOLGNOM2

REGULATORY

UCITS Compliant	Yes
ISA Eligibility	Yes
SIPP Available	Yes
UK Reporting Status	Yes

PERFORMANCE (%)

	YTD	1M	3M	12M	Since Inception
ETF	5.04%	0.12%	4.40%	31.18%	-44.62%
Index	5.13%	0.18%	4.49%	31.77%	-43.43%
Difference	-0.09%	-0.06%	-0.09%	-0.59%	-1.19%

Performance is based on the fund's NAV and is shown on a total return basis (i.e., with gross income reinvested, where applicable). The fund's NAV may differ from its market price and, as a result, individual shareholders may realize returns that are different from the NAV performance. Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualised return is the average return gained or lost by an investment each year over a given time period.


The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance, when observed, is unusual and investors should not expect such performance to be repeated. The return of your investment may increase or decrease as a result of currency fluctuations if your investment is made in a currency other than that used in past performance calculations.

TOP 10 HOLDINGS (%)


Company	Percentage	Company	Percentage
Moderna Inc	8.20%	Vertex Pharmaceuticals Inc	4.50%
Praxis Precision Medicines I	6.50%	Biomarin Pharmaceutical Inc	4.50%
Arrowhead Pharmaceuticals In	5.93%	Natera Inc	4.08%
Illumina Inc	5.35%	Biontech Se-Adr	4.03%
Guardant Health Inc	4.91%	Qiagen N.V.	3.79%

Holdings Subject to Change

SECTOR BREAKDOWN (%)



COUNTRY BREAKDOWN (%)





EXPANDED TRADING INFORMATION

USD Accumulating (ISIN: IE00BM8R0N95)

EXCHANGE	TRADING CURRENCY	TICKER	LISTING DATE	SEDOL
London Stock Exchange	USD	GNOM LN	4-Nov-21	BP49D86
London Stock Exchange	GBP	GNOG LN	4-Nov-21	BP49D97
Deutsche Börse Xetra	EUR	GNOM GY	11-Nov-21	BP49DB9
SIX Swiss Exchange	CHF	GNOM SW	6-Dec-21	BP49DC0
Borsa Italiana	EUR	GNOM IM	18-Nov-21	BP49DD1

DEFINITIONS

Solactive Genomics v2 Index	The Solactive Genomics v2 Index tracks the companies that generate revenues from Genomics related business. Genomics business operations include the following: (I) gene editing, (II) genomic sequencing, (III) development and testing of genetic medicine/therapies, (IV) computational genomics and genetic diagnostics, and/or (V) biotechnology.
-----------------------------	--

A Prospectus and Key Investor Information Document (KIID) for this scheme is available in English at globalxetfs.eu/funds/GNOM

¹Ongoing Charges is a measure of the total costs associated with managing and operating an investment fund. These costs consist primarily of management fees and other expenses such as trustee, custody, transaction and registration fees, and other operating expenses. The total cost for the fund is divided by the fund's total assets and expressed as a percentage.

The Global X UCITS ETFs are regulated by the Central Bank of Ireland.

This is a marketing communication.

Please refer to the relevant prospectus, supplement, and the Key Information Document ("KID") of the relevant UCITS ETFs before making any final investment decisions.

Investors should also refer to the section entitled "Risk Factors" in the relevant prospectus of the UCITS ETFs in advance of any investment decision for information on the risks associated with an investment in the UCITS ETFs, and for details on portfolio transparency. The relevant prospectus and KID for the UCITS ETFs are available in English at www.globalxetfs.eu/funds.

Investment in the UCITS ETFs concern the purchase of shares in the UCITS ETFs and not in a given underlying asset such as a building or shares of a company, as these are only the underlying assets that may be owned by the UCITS ETFs.

A UCITS ETF's shares purchased on the secondary market cannot usually be sold directly back to a UCITS ETF. Investors must buy and sell shares on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying shares and may receive less than the current net asset value when selling them. Changes in exchange rates may have an adverse effect on the value price or income of the UCITS ETF.

Past performance of a UCITS ETF does not predict future returns. Future performance is subject to taxation which depends on the personal situation of each investor, and which may change in the future. Neither past experience nor the current situation are necessarily accurate guides to the future growth in value or rate of return of a UCITS ETF.

Investment may be subject to sudden and large falls in value, and, if it is the case, the investor could lose the total value of the initial investment. Income may fluctuate in accordance with market conditions and taxation arrangements. The difference at any one time between the sale and repurchase price of a share in the UCITS ETF means that the investment should be viewed as medium term to long term.

Any investment in a UCITS ETF may lead to a financial loss. The value of an investment can reduce as well as increase and, therefore, the return on the investment will be variable.

Global X ETFs ICAV is an open-ended Irish collective asset management vehicle issuing under the terms of its prospectus and relevant supplements as approved by the Central Bank of Ireland and is the issuer of certain of the ETFs where stated.

Global X ETFs ICAV II is an open-ended Irish collective asset management vehicle issuing under the terms of its prospectus and relevant supplements as approved by the Central Bank of Ireland and is the issuer of certain of the ETFs where stated.

Communications issued in the European Union relating to Global X UCITS ETFs are issued by Global X Management Company (Europe) Limited ("GXM Europe") acting in its capacity as management company of Global X ETFs ICAV. GXM Europe is authorised and regulated by the Central Bank of Ireland. GXM Europe is registered in Ireland with registration number 711633.

Communications issued in the United Kingdom and Switzerland relating to Global X UCITS ETFs are issued by Global X Management Company (UK) Limited ("GXM UK"), which is authorised and regulated by the Financial Conduct Authority. The registered office of GXM UK is 77 Coleman St, EC2R 5BJ, UK. Information about GXM UK can be found on the Financial Services Register (register number 965081).

Information for Investors in Switzerland

This is an advertising document. The state of the origin of the fund is Ireland. In Switzerland, the representative is 1741 Fund Solutions AG, Burggraben 16, CH-9000 St.Gallen. The paying agent is Tellco Bank Ltd, Bahnhofstrasse 4, 6430 Schwyz.

The prospectus, the key information documents, the articles of association as well as the annual and semi-annual reports may be obtained free of charge from the representative.

Past performance is no indication of current or future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units.